Clinical Trial Update: Phase IB Trial of LDE225 and Paclitaxel in Recurrent Ovarian Cancer [Phase 1]

View source ↗

Summary

This update indicates the Phase 1b trial combining LDE225 (sonidegib) with paclitaxel in recurrent ovarian cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• LDE225 (sonidegib)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Recurrent Ovarian Cancer | Phase 1 | Status: COMPLETED